Pandemic influenza and the global vaccine supply

Clinical Infectious Diseases

Volumn 36, Issue 12, 2003, Pages 1552-1561

  Fedson, David S ^a  

^a NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

DEVELOPING COUNTRY; DISEASE PREDISPOSITION; DRUG FORMULATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; EPIDEMIOLOGICAL DATA; HEALTH CARE PLANNING; HUMAN; INFECTION CONTROL; INFLUENZA; INFLUENZA VACCINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REGISTRATION; REVIEW; VACCINE PRODUCTION; VIRUS STRAIN; ARTICLE; DRUG INDUSTRY; EPIDEMIC; VACCINATION; WORLD HEALTH ORGANIZATION;

DISEASE OUTBREAKS; DRUG INDUSTRY; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINATION; WORLD HEALTH ORGANIZATION;

EID: 0038037687     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/375056     Document Type: Review

References (48)

1. Flewett TH. Introduction to symposium on influenza in hospital and elsewhere. Postgard Med J 1963; 39:563.
2. Gladwell M. Talk of the town. The New Yorker 29 October 2001:33-4
3. Cox NJ, Subbarao K. Influenza. Lancet 1999; 354:1277-82.
4. Simonsen L. The global impact of influenza on morbidity and mortality. Vaccine 1999; 17(Suppl 1):S3-10.
5. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2002; 51(RR-3):1-31.
6. Vu T, Farish S, Jenkins M, Kelly H. A meta-analysis of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 2002; 20:1831-6.
7. Scuffham P, West PA. Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine 2002; 20:2562-78.
8. Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 2003; 21:1769-75
9. Ambrosch F, Fedson DS. Influenza vaccination in 29 countries: an update to 1997. Pharmacoeconomics 1999; 16(Suppl 1):47-54.
10. van Essen GA, Palache AM, Forleo E, Fedson DS. Influenza vaccination in 2000: recommendations and vaccine use in 50 developed and rapidly developing countries. Vaccine 2003; 21:1780-5.
11. Glezen WP. Emerging infections: pandemic influenza. Epidemiol Rev 1996; 18:64-76.
12. Snacken R, Kendal AP, Haaheim LR, Wood JM. The next influenza pandemic: lessons from Hong Kong, 1997. Emerg Infect Dis 1999; 5:195-203.
13. Meltzer MI, Cox NJ, Fukuda K. The impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis 5:659-71.
14. Schoch-Spana M. Implications of pandemic influenza for bioterrorism response. Clin Infect Dis 2000; 31:1409-13.
15. Schoenbaum SC. The impact of pandemic influenza, with special reference to 1918. In: Osterhaus ADME, Hampson A, Cox NJ, eds. Options for the control of influenza IV: proceedings of the World Congress on Options for the Control of Influenza IV. International Congress Series 1219. Amsterdam: Elsevier Science, 2001:43-51.
16. Nguyen-Van-Tam JS, Hampson AW. The epidemiology and clinical impact of pandemic influenza. Vaccine 2003; 21:1762-8.
17. Fedson DS. The epidemiology of influenza vaccination: implications for global vaccine supply for an influenza pandemic. In: Osterhaus ADME, Hampson A, Cox NJ, eds. Options for the control of influenza IV: proceedings of the World Congress on Options for the Control of Influenza IV. International Congress Series 1219. Amsterdam: Elsevier Science, 2001:723-31.
18. Division of Health Situation and Trend Assessment. Demographic data for health situation assessment and projection, 1996. Geneva: World Health Organization, 1996:91-176.
19. Simonsen L, Clarke MJ, Schonberger LB, Arden NH, Cox NJ, Fukuda K. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J Infect Dis 1998; 178:53-60.
20. Reichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 2001; 344:889-96.
21. Treanor JJ, Wilkinson BE, Masseoud F, et al. Safety and immunogenicity of a recombinant vaccine for H5 influenza in humans. Vaccine 2001; 19:1732-7.
22. Nicholson KG, Colegate AE, Podda A, et al. Safety and antigenicity of non-adjuvanted and MF-59 adjuvanted A/Duck/Singapore/97 (H5N3) vaccine: a randomized trial of two potential vaccines against H5N1 influenza. Lancet 2001; 357:1937-43.
23. Wood JM. Developing vaccines against pandemic influenza. Philos Trans R Soc Lond B Biol Sci 2001; 356:1953-60.
24. Hehme N, Engelmann H, Künzel W, Neumeier E, Sanger R. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol (Berl) 2002; 191:203-8.
25. Schoenbaum SC, McNeil BJ, Kavet J. The swine-influenza vaccine decision. N Engl J Med 1976; 295:759-65.
26. Hilleman MR. Cooperation between government and industry in combating a perceived emerging pandemic: the 1976 Swine Influenza Vaccination Program. JAMA 1996; 275:241-3.
27. Dowdle WR. Pandemic influenza: confronting the re-emergent threat. The 1976 experience. J Infect Dis 1997; 176(Suppl 1):S69-S72.
28. World Health Organization. Influenza pandemic preparedness plan: responding to an influenza pandemic or its threat - the role of WHO and guidelines for national and regional planning. Geneva: World Health Organization, 1999. Available at: http://www.who.int/csr/resources/ publications/influenza/WHO_CDS_CSR_EDC_99_1/en/. Accessed 3 June 2003.
29. Paget WJ, Aguilera J-F. Influenza pandemic planning in Europe. Eurosurveillance 2001; 6:136-40.
30. Neumann G, Kawaoka Y. Reverse genetics of influenza virus. Virology 2001; 287:243-60.
31. Palache AM, Beyer WEP, Luchter G, Voler R, Sprenger MJW, Masurel N. Influenza vaccines: the effect of vaccine dose on antibody response in primed populations during the ongoing interpandemic period - a review of the literature. Vaccine 1993; 11:892-908.
32. Treanor J, Keitel W, Belshe R, et al. Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults. Vaccine 2002; 20:1099-105.
33. Parkman PP, Hopps HE, Rastogi SC, Meyer HM Jr. Summary of clinical trials of influenza virus vaccines in adults. J Infect Dis 1977; 136(Suppl):S722-30.
34. Wright PF, Thompson J, Vaughn WK, Folland DS, Sell SHW, Karzon DT. Trials of influenza A/New Jersey/76 virus vaccine in normal children: an overview of age-related antigenicity and reactogenicity. J Infect Dis 1977; 136(Suppl):S731-41.
35. La Montagne JR, Noble GR, Quinnan GV, et al. Summary of clinical trials of inactivated influenza vaccine - 1978. Rev Infect Dis 1983; 5:723-36.
36. Edwards KM, Meade BD, Decker MD, et al. Comparison of 13 acellular persussis vaccines: overview and serologic response. Pediatrics 1995; 96:548-57.
37. Schabas RE. Mass influenza vaccination in Ontario: a sensible move. CMAJ 2001; 164:36-7.
38. World Health Organization. Influenza vaccines. WHO position paper. Wkly Epidemiol Rec 2002; 77:230-9.
39. Nichol KL. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med 2001; 161:749-59.
40. Muenning PA, Khan K. Cost-effectiveness of vaccination versus treatment of influenza in healthy adolescents and adults. Clin Infect Dis 2001; 33:1879-85.
41. Pandemic preparedness in the community: influenza and other health threats. Preliminary conclusions and recommendations of a conference held in Brussels, 27 November 2001. Available at: http://europa.eu.int/comm/health/ph_threats/com/ Influenza/influenza_conference_1.htm. Accessed 26 April 2002.
42. Global agenda on influenza - adopted version. Wkly Epidemiol Rec 2002; 77:179-82.
43. Adoption of global agenda on influenza - part II. Wkly Epidemiol Rec 2002; 77:191-5.
44. Horimoto T, Kawaoka Y. Pandemic threat posed by avian influenza A viruses. Clin Microbiol Rev 2001; 14:129-49.
45. Hatta M, Gao P, Halfmann P, Kawaoka Y. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science 2001; 293:1840-2.
46. Ha Y, Stevens DJ, Skehel JJ, Wiley DC. H5 and H9 swine influenza virus haemagglutinin structures: possible origin of influenza subtypes. EMBO J 2002; 21:865-75.
47. Seo SH, Hoffmann E, Webster RG. Lethal H5N1 influenza viruses escape host anti-viral cytokine responses. Nat Med 2002; 8:950-4.
48. Cheung CY, Poon LLM, Lau AS. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 2002; 360:1831-7.